{"id":"NCT01938001","sponsor":"Celgene","briefTitle":"Rituximab Plus Lenalidomide for Patients With Relapsed / Refractory Indolent Non-Hodgkin's Lymphoma (Follicular Lymphoma and Marginal Zone Lymphoma)","officialTitle":"A Phase 3, Double-blind, Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Placebo in Subjects With Relapsed/Refractory Indolent Lymphoma","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-11-21","primaryCompletion":"2018-06-22","completion":"2022-01-26","firstPosted":"2013-09-10","resultsPosted":"2019-08-13","lastUpdate":"2023-02-22"},"enrollment":358,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Lymphoma, Non-Hodgkin"],"interventions":[{"type":"DRUG","name":"Rituximab","otherNames":["Rituxan"]},{"type":"DRUG","name":"Lenalidomide","otherNames":["CC-5013, Revlimid"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Rituximab and Lenalidomide","type":"EXPERIMENTAL"},{"label":"Rituximab and Placebo","type":"ACTIVE_COMPARATOR"}],"summary":"This double-blind randomized, parallel group study will evaluate the efficacy and safety of lenalidomide (Revlimid, CC-5013) in combination with rituximab (MabThera/Rituxan) in patients with relapsed or refractory follicular lymphoma or marginal zone lymphoma. Patients will be randomized to receive either lenalidomide or placebo for twelve 28-day cycles in combination with rituximab. Anticipated time on study treatment is 1 year.","primaryOutcome":{"measure":"Kaplan Meier Estimate of Progression Free Survival Assessed by the Independent Review Committee (IRC) According to the 2007 International Working Group Response Criteria (IWGRC)","timeFrame":"From randomization of study drug up to disease progression or death, which occurred first; up to the data cut-off date of 22 June 2018; overall median follow-up time for all participants was 28.30 months (range: 0.1 to 51.3 months).","effectByArm":[{"arm":"Rituximab + Lenalidomide (R^2)","deltaMin":39.4,"sd":null},{"arm":"Rituximab + Placebo","deltaMin":14.1,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"< 0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":11,"exclusionCount":17},"locations":{"siteCount":160,"countries":["United States","Belgium","Brazil","China","Czechia","France","Germany","Israel","Italy","Japan","Poland","Portugal","Puerto Rico","Russia","Spain","Turkey (TÃ¼rkiye)","United Kingdom"]},"refs":{"pmids":["30184451","30897038"],"seeAlso":["https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html","https://www.bmsstudyconnect.com/s/US/English/USenHome","http://www.fda.gov/safety/medwatch/safetyinformation/default.htm"]},"adverseEventsSummary":{"seriousAny":{"events":45,"n":176},"commonTop":["Neutropenia","Diarrhoea","Constipation","Fatigue","Cough"]}}